Hyperactivation of the Corticotropin-Releasing Hormone (CRH, also referred to as CRF) system describes a condition of excessive tone or reactivity of the circuits that orchestrate the stress response, with neuroendocrine, metabolic, immune and behavioral repercussions. In its physiological role, hypothalamic CRH initiates the hypothalamic-pituitary-adrenal axis by inducing secretion of ACTH and, downstream, glucocorticoids; however, CRH is also an extrahypothalamic neuromodulator, active in limbic and brainstem circuits, where it influences arousal, anxiety, attention, memory consolidation and autonomic responses. CRH dysregulation, therefore, does not necessarily correspond to a single “disease”, but to a pathophysiological pattern capable of producing different clinical phenotypes depending on intensity, duration, individual vulnerability and biological context.
In clinical endocrinology, the relevance of CRH hyperactivation emerges mainly for three reasons: its ability to sustain persistent or intermittent hypercortisolism, its potential to mimic true hypercortisolism by generating pseudo-Cushing states in contexts of chronic stress and systemic illness, and its contribution to the pathogenesis of stress-axis dysfunctions in psychiatric and inflammatory disorders. The correct approach requires distinguishing the adaptive physiology of the stress response from conditions in which the system becomes maladaptive, self-perpetuating and clinically harmful.
Quantifying the epidemiology of CRH hyperactivation is complex because there is no single universal biomarker, and because dysfunction of the CRH system may manifest as central hyperactivity with variable peripheral patterns of the hypothalamic-pituitary-adrenal axis. Clinically, the condition is detected in three main domains: stress- and trauma-related disorders, phenotypes of true or apparent hypercortisolism, and conditions of chronic inflammation and systemic illness in which the stress response becomes persistent. In each of these contexts, prevalence depends on the criterion used to “define” dysregulation: circadian alterations in cortisol, loss of dexamethasone suppression, increased response to stress stimuli, or indirect evidence of CRH hyperactivity in central compartments.
The first major group is chronic stress, understood as prolonged exposure to psychological, occupational, social or medical stressors. The duration of stress is decisive because the acute response, mediated by CRH and catecholamines, is physiological and protective; it is chronicity that can transform an adaptation circuit into a vulnerability circuit, with synaptic remodeling and changes in receptor sensitivity. In this framework, individual vulnerability depends on genetic, epigenetic and developmental factors, with a particularly relevant role for early adverse experiences, which can “program” the reactivity of the CRH system and the stress axis throughout the life course.
A second group includes psychiatric and neurobiological conditions associated with hyperactivity of the CRH system, such as some phenotypes of major depression, anxiety disorders and trauma-related conditions. In these contexts, the most consistent evidence concerns alterations in central CRH and related systems, with consequent increase in arousal and changes in the stress response, which may coexist with peripheral cortisol levels that are not necessarily constantly elevated. Interindividual variability is high and depends on clinical subtypes, comorbidities, medications, sleep and inflammatory status.
The third group is represented by conditions that can produce a biochemical “imprint” similar to hypercortisolism, although they are not sustained by a neoplasm or by a classic endocrine cause. Chronic alcohol abuse, some forms of severe depression, malnutrition, chronic diseases and systemic inflammation can alter axis regulation and generate pseudo-Cushing states, in which activation of the stress system is a pathophysiological driver. In these situations, the risk factor is not a single agent but the convergence of metabolic stress, inflammation and sleep alterations, all of which can reinforce the activity of CRH circuits.
Finally, there are rare but conceptually decisive conditions: hypercortisolism sustained by ectopic CRH production, in which dysregulation is not functional but “biologically iatrogenic”, because CRH is secreted by a tumor and activates the axis upstream. Although exceptional, these cases are important because they directly demonstrate how an excess of CRH can produce severe hypercortisolism and because they can mimic a pituitary form due to laboratory patterns and dynamic test results, imposing a rigorous diagnostic pathway.
CRH hyperactivation can be interpreted as the result of an increased “demand” for stress response, a reduced capacity to switch off the circuit, or an abnormal autonomous activation of the system. From an etiological perspective, it is useful to distinguish a functional excess of CRH, related to stressors or neurobiological vulnerability, from an organic excess, sustained by lesions or ectopic production. In most patients the component is functional, but the clinical task is to recognize when the pathophysiological pattern requires exclusion of true endocrine hypercortisolism or a structural cause.
In the brain, CRH is produced mainly by neurons of the paraventricular nucleus of the hypothalamus to activate the hypothalamic-pituitary-adrenal axis, but also by extrahypothalamic circuits, including the amygdala, the bed nucleus of the stria terminalis and other regions that modulate fear, vigilance and autonomic response. This dual nature explains why CRH hyperactivation may present as an endocrine syndrome, namely hypercortisolism, or as a neurobehavioral syndrome, namely hyperarousal, anxiety, insomnia and alterations in emotional memory, or as a combination of the two. The peripheral response also depends on the balance between CRH1 and CRH2 receptors and on the presence of CRH-binding protein, which modulates ligand bioavailability in specific compartments.
The pathophysiology of the stress axis is defined by a central principle: the information is not only “how much” cortisol is produced, but “how” it is distributed over time. The CRH system coordinates ACTH and cortisol secretion, which normally follows a circadian rhythm and acute reactivity to stressors. In dysregulation, the rhythm may become flattened, shifted earlier or fragmented, with loss of the physiological evening and night-time decline. This phenomenon has high clinical value because loss of the temporal physiology of cortisol is one of the mechanisms through which hyperactivity of the stress system becomes pathogenic even in the absence of constantly elevated hypercortisolism.
A second pathophysiological node is the quality of negative glucocorticoid feedback. Under physiological conditions, increased cortisol reduces CRH and ACTH through feedback mediated by the glucocorticoid receptor in the hypothalamus, pituitary gland and limbic circuits. In some contexts of chronic stress and inflammation, a form of glucocorticoid resistance may develop, in which feedback weakens: the system continues to perceive a signal of “insufficiency” and maintains CRH and ACTH activation. This dynamic is crucial because it makes it possible to understand how signs of high biological stress can coexist with pro-inflammatory immune patterns and metabolic alterations, despite the presence of circulating cortisol.
At the metabolic and cardiovascular level, hyperactivation of CRH and of the stress axis promotes an energy reconfiguration oriented toward survival: increased glucose availability, lipolysis and proteolysis, modulation of appetite and adipose tissue distribution. When persistent, this adaptive program becomes harmful and contributes to insulin resistance, increased visceral fat, dyslipidemia and blood pressure alterations. In parallel, extrahypothalamic CRH and the sympathetic system amplify tachycardia, vasoconstriction and autonomic hyperreactivity, providing the bridge between chronic stress and cardiometabolic risk.
In the central nervous system, CRH hyperactivation acts as an amplifier of arousal and stimulus salience, promoting insomnia, hypervigilance and consolidation of negative emotional memories. In the long term, prolonged exposure to glucocorticoids and CRH-dependent activity can influence synaptic plasticity and neurogenesis in key regions for memory and emotional regulation. This part of the pathophysiology clarifies why dysfunction of the CRH system may maintain symptoms even when the external stressor has decreased, transforming the stress response into a self-perpetuating circuit.
Finally, the “purest” form of CRH excess is that sustained by ectopic secretion: a tumor may produce CRH, which stimulates the pituitary gland, increasing ACTH and cortisol. The pathophysiological point is that the pituitary gland remains responsive to CRH and may show patterns that simulate a pituitary form, including the response to some dynamic tests, making it indispensable to integrate biochemistry, imaging and, in selected cases, inferior petrosal sinus sampling with expert interpretation.
The clinical manifestations of CRH hyperactivation depend on the proportion of activation of the hypothalamic-pituitary-adrenal axis compared with the extrahypothalamic and autonomic component. The presentation may fluctuate between phenotypes dominated by neurovegetative and psychological symptoms and phenotypes dominated by somatic signs of hypercortisolism. The clinical task is to reconstruct the chronology: when the symptoms began, whether a trigger exists, how they are distributed over time, and whether the patient has circadian fluctuations or episodes related to stressful events.
From the history-taking perspective, the most frequent symptoms include insomnia with difficulty falling asleep or early awakenings, hypervigilance, irritability, reduced tolerance to stress, somatization and anxiety symptoms. Reduced concentration, easy fatigability and memory alterations may appear, often described as a “mind that is always switched on”. In parallel, autonomic symptoms such as palpitations, sweating, fine tremor and blood pressure instability may be present, especially during periods of greater arousal or in the presence of stimuli perceived as threatening.
When activation of the stress axis is marked and persistent, signs compatible with hypercortisolism may emerge, although not always with the full picture of classic Cushing syndrome. The patient may report centripetal weight gain, increased appetite or, in some subtypes, weight loss associated with autonomic hyperactivation. The history may include worsening glycemic control, onset of hypertension or worsening of already elevated blood pressure, reduced exercise tolerance and proximal weakness, especially in the lower limbs.
On physical examination, in cases with true hypercortisolism, more specific features may be observed: skin fragility, bruising, wide violaceous striae, rounded face, dorsocervical fat accumulation and reduction in proximal muscle mass. However, in functional dysregulation of the stress system, signs may be more subtle and overlap with common conditions such as obesity, metabolic syndrome and mood disorders. For this reason, the physical examination must be interpreted in integration with the temporal history and biochemical data.
A clinically relevant area is symptomatology related to immune and inflammatory dysregulation: flare-ups of inflammatory conditions, greater susceptibility to infections in some contexts, or coexistence of systemic symptoms such as widespread pain and asthenia. These manifestations reflect the complex interaction between glucocorticoids, catecholamines and immune mediators, and may contribute to a global perception of illness that reinforces stress and fuels the CRH circuit.
In rare forms of ectopic CRH secretion, the clinical picture tends to be that of severe and rapidly progressive hypercortisolism, with hypokalemia, rapid worsening of hypertension and diabetes, opportunistic infections and marked muscle weakness. In these cases, the speed of progression and systemic severity become key elements for differentiating a functional disorder from a high-risk endocrine syndrome.
Suspicion of CRH hyperactivation should arise when the clinician recognizes a pattern of persistent symptoms of biological stress, not explained by a single acute event and disproportionate to contextual factors, or when signs compatible with hypercortisolism appear and require exclusion of Cushing syndrome. It is essential to start from a precise clinical question: is the problem primarily a neurobehavioral disorder with possible dysfunction of the stress axis, or is it a suspicion of endocrine hypercortisolism that requires confirmation and etiological definition.
Suspicion is particularly appropriate in the presence of persistent insomnia, hyperarousal and autonomic symptoms associated with worsening cardiometabolic parameters, especially if the history includes chronic stress, trauma, depressive or anxiety disorder, or chronic inflammatory disease. In these patients, attention should be directed to the temporal alterations of symptoms, sleep quality and the conditions that amplify the stress response, because dysfunction of the CRH system often manifests as loss of evening and night-time “switch-off”.
Suspicion must become stronger when more specific clinical signs of hypercortisolism appear or when the evolution is rapid and progressive. The combination of marked proximal weakness, skin fragility, spontaneous bruising, wide violaceous striae, recent or resistant hypertension and rapid worsening of glycemic control should orient toward a diagnostic pathway for Cushing syndrome. In this scenario, CRH hyperactivation is relevant both as a possible central mechanism in functional conditions and, rarely, as a direct cause through ectopic secretion.
A high-priority clinical context is pseudo-Cushing states: patients with alcoholism, severe depression or systemic stress who present overlapping clinical features and borderline screening tests. In these cases, suspicion is not “less important” than in true Cushing syndrome, because the practical consequence is choosing a diagnostic pathway that reduces false positives and false negatives, and that integrates correction of the trigger with reasoned repetition of tests under standardized conditions.
Finally, suspicion of CRH excess as an organic event should be considered when hypercortisolism is severe, with elevated ACTH, and when localization of the ACTH source is discordant or confusing. In these cases, the possibility that a tumor produces CRH, stimulating the pituitary gland, must be maintained in the differential reasoning, especially if the picture does not behave like a classic pituitary form or if imaging and dynamic tests generate inconsistencies.
The operational diagnosis of stress-axis dysregulation mediated by the CRH system requires a sequential approach that separates two objectives: demonstrating or excluding endocrine hypercortisolism and, in parallel, characterizing the temporal and reactive dysfunction of the system in patients with a chronic stress phenotype. Since central CRH is not easily measurable in routine clinical practice, diagnosis is based on cortisol and ACTH patterns, dynamic tests and clinical coherence.
When the main suspicion is Cushing syndrome, the first step is biochemical screening with validated tests. The choice of test depends on the context, but generally includes late-night salivary cortisol, 24-hour urinary free cortisol and the low-dose dexamethasone suppression test. Interpretation must take into account comorbidities, medications, sleep disorders and conditions that alter corticosteroid-binding globulin. It is essential to repeat and confirm abnormal results before proceeding to etiological investigations, especially when the pre-test probability is intermediate and clinical signs are not highly specific.
In pseudo-Cushing states, activation of the stress system can produce alterations that overlap with screening tests, reducing their specificity. In these patients, the diagnostic strategy should include correction of the trigger when possible and reassessment under stable conditions. It is at this stage that a careful history of alcohol use, depression, sleep disorders and systemic stress becomes an integral part of diagnosis. The goal is to avoid labeling as neoplastic endocrinopathy a condition that may normalize with treatment of the functional cause.
If screening confirms hypercortisolism, the next step is to distinguish ACTH-independent forms from ACTH-dependent forms through plasma ACTH and integrated interpretation. In ACTH-dependent forms, reasoning about the source comes into play: pituitary gland, ectopic ACTH or, rarely, ectopic CRH. The rarity of ectopic CRH does not nullify its importance, because it can confuse localization tests: an excess of CRH can induce corticotroph hyperplasia and patterns that simulate a pituitary source.
In selected cases, dynamic tests and inferior petrosal sinus sampling can be used to localize the source of ACTH stimulation. Interpretation must be expert because the physiology of CRH can alter the pituitary response. In the presence of discordance between biochemistry, pituitary imaging and sampling results, the possibility of pituitary stimulation secondary to ectopic CRH must be maintained, requiring an accurate search for the primary lesion and targeted oncological assessment.
In patients whose objective is not to confirm Cushing syndrome but to characterize dysfunction of the stress axis, investigations have a different orientation. It is often useful to document the circadian pattern of cortisol, its relationship with sleep and stressors, and to evaluate endocrine and internal medicine comorbidities that amplify the stress response. Hypothalamic-pituitary imaging is not routine in the absence of suspicion of a lesion, but becomes indicated if there are signs of central disease, multiple pituitary deficits, worsening headache, visual disturbances or a history of trauma and cranial treatments.
The classification of CRH hyperactivation is useful only if it guides clinical management, because the CRH system is a network node and its dysregulation takes different forms. A first classification axis distinguishes functional dysregulation from organic dysregulation. The functional form includes chronic stress, psychiatric disorders, pseudo-Cushing states and inflammatory conditions; the organic form includes true endocrine hypercortisolism and, exceptionally, ectopic CRH secretion. This distinction is not a judgment of severity, but a guide for choosing tests, reassessment timing and therapeutic priorities.
A second classification axis concerns the peripheral profile of the hypothalamic-pituitary-adrenal axis. Some patients show a phenotype of persistent hypercortisolism or loss of the night-time nadir; others present excessive reactivity to stressors with basal values that are not dramatically elevated; still others show dissociation between symptoms and peripheral levels, presumably due to predominance of extrahypothalamic and autonomic CRH circuits. In clinical practice, this means that severity does not always correspond to a single cortisol value, but to the combination of loss of rhythmicity, cardiometabolic impact and functional impairment.
A third criterion classifies forms according to temporality: acute and circumscribed episodes, intermittent forms, and chronic self-perpetuating forms. Temporality is fundamental because it defines different objectives. In acute forms, the objective is resolution of the trigger and restoration of sleep; in intermittent forms, it is crucial to identify repeatable patterns and precipitating factors; in chronic forms, a long-term plan is necessary, including interventions on lifestyle, psychopathology and metabolic comorbidities.
Finally, a clinically relevant criterion is the presence or absence of organ complications attributable to chronic activation of the axis: osteopenia or bone loss, worsening glycemic control, resistant hypertension, functional sarcopenia, recurrent infections in true hypercortisolism. The presence of complications shifts the decision-making axis toward structured endocrine assessment and, if necessary, specific cortisol-directed therapy, whereas the absence of complications with symptoms dominated by arousal points toward treatment centered on sleep, stress and neurobiological circuits.
The treatment of CRH hyperactivation must start from the distinction between true endocrine hypercortisolism and functional dysregulation of the stress system, because the therapeutic objective changes radically. In endogenous Cushing syndrome, the priority is to remove or control the source of hypercortisolism and protect the patient from acute and chronic complications. In functional dysregulation, the objective is to switch off the maladaptive circuit by restoring rhythmicity, sleep, energy balance and reducing exposure to persistent stressors or their neurobiological amplification.
When confirmed hypercortisolism is present, therapy follows guideline principles: removal of the causal lesion when possible, or medical control of cortisol and management of complications. In ACTH-dependent forms, the strategy depends on the etiology; in forms sustained by ectopic CRH, definitive therapy consists of controlling the responsible tumor and managing cortisol, often urgently because hypercortisolism can be severe. In these contexts, multidisciplinary collaboration is essential because CRH hyperactivation is a mechanism that expresses itself as a high-risk systemic syndrome.
In functional forms, therapy is centered on interventions that reduce baseline activation and restore the ability to switch off in the evening and at night. Correction of sleep is often the first high-yield clinical intervention, because insomnia keeps arousal elevated and amplifies the stress axis. In parallel, it is fundamental to act on metabolic and behavioral factors that function as biological stressors: irregular meals, reactive hypoglycemia, sedentary lifestyle, excessive stimulant intake, or uncontrolled chronic pain. In many patients, reducing the “allostatic load” is the step that allows the CRH system to downscale its activity without the need for specific endocrine therapies.
Treatment of psychiatric disorders and trauma-related disorders is an integral part of management when the clinical phenotype requires it. The pathophysiological point is that effective therapy reduces the network activity that feeds central CRH, lowering hypervigilance and improving sleep, with positive effects also on cardiometabolic parameters. In these cases, pharmacological and psychotherapeutic treatment must be integrated with targeted endocrinological assessment when signs or tests compatible with hypercortisolism exist or when metabolic comorbidities are relevant.
At the experimental and translational pharmacological level, CRH1 receptor antagonists have been developed with the aim of reducing arousal and stress response. Clinical studies in anxiety disorders, depression and PTSD have shown globally limited results as monotherapy, suggesting that the complexity of CRH circuits and the variability of clinical phenotypes make a “one size fits all” approach difficult. This does not eliminate scientific interest, but imposes a critical reading: CRH hyperactivation is a network node and may require subgroup selection, biomarkers and combined strategies, rather than a single antagonist administered indiscriminately.
In pseudo-Cushing conditions, effective treatment is treatment of the trigger: alcohol abstinence in alcohol-related conditions, treatment of depression and normalization of sleep in psychiatric conditions, correction of malnutrition and systemic stress. Normalization of the stress-axis profile is part of the outcome and also represents a practical criterion for avoiding unnecessary invasive diagnostic pathways.
Follow-up must be built according to the clinical form. In the patient with true hypercortisolism, monitoring is centered on remission, recurrence and management of complications, with scheduled biochemical controls and structured clinical assessment of blood pressure, glycemia, thrombotic risk, infections and bone health. Cortisol rhythmicity and neuropsychiatric symptoms must also be reassessed after correction of hypercortisolism, because part of the clinical burden may persist for months and require targeted interventions on sleep, mood and functional performance.
In functional forms, follow-up serves to document reduction of allostatic load and recovery of the system’s ability to switch off. Clinical indicators include sleep, mood stability, reduction of hypervigilance, blood pressure control and improvement in metabolic parameters. In some patients, it is useful to repeat cortisol measurements at standardized times, especially when tests were borderline during the diagnostic phase and when the aim is to demonstrate a trend toward normalization after correction of the trigger.
Skeletal health is a cross-sectional monitoring axis in patients with suspected or documented persistent hypercortisolism or prolonged exposure to high biological stress. In more severe or prolonged cases, bone densitometry and assessment of fracture risk may become part of follow-up, integrating vitamins, nutritional status and physical activity. Even in patients without overt Cushing syndrome, the combination of insomnia, sedentary lifestyle and metabolic alterations can promote loss of muscle mass and reduction of physical resilience, making periodic functional assessment useful.
A practical point is reassessment of medications and substances that influence the stress system: stimulants, exogenous glucocorticoids, including high-dose topical or inhaled forms, substances of abuse and some psychotropic medications can alter test interpretation and maintain symptoms. Follow-up must therefore include active control of pharmacological exposure and lifestyle habits that modulate CRH, particularly sleep, nutrition and physical activity.
In patients with trauma-related disorders or depression, follow-up integrated with psychiatry and psychology is often decisive because reduction of CRH-dependent hyperactivity requires emotional stabilization, reduction of hyperarousal and recovery of rhythms. The criterion of efficacy is not only symptom reduction, but restoration of a stable trajectory over time, with decreased reactive fluctuations to stressors.
The prognosis of CRH hyperactivation is heterogeneous because it depends on the cause and duration of dysregulation. In functional forms, prognosis may be favorable if the stressor is reduced, sleep is restored and psychiatric and metabolic comorbidities are treated effectively. However, when dysregulation is prolonged and becomes self-perpetuating, the course may be chronic and require integrated long-term strategies, not only to reduce symptoms but also to prevent cardiometabolic and functional complications.
The main complications are related to the chronic effects of the stress system on metabolism, the cardiovascular apparatus, the musculoskeletal system and immunity. Persistent activation promotes insulin resistance, increased visceral fat and worsening lipid profile, with consequent increase in cardiovascular risk. In parallel, hypervigilance and insomnia become maintaining factors that increase low-grade inflammation and worsen blood pressure control, creating a circuit between biological stress and cardiometabolic risk.
At the musculoskeletal level, prolonged exposure to elevated endogenous glucocorticoids, even if intermittent, can contribute to loss of muscle mass and reduction of proximal strength, with consequent functional limitation. In true hypercortisolism, bone loss and increased fracture risk represent complications of major clinical weight and require specific prevention and treatment. Even in functional forms, the combination of inactivity, inflammation and disturbed sleep can reduce muscle performance and physical resilience, affecting quality of life.
Neuropsychiatric complications include chronicization of insomnia, worsening of anxiety, depressive vulnerability and reduced capacity for emotional regulation. In some patients, central CRH hyperactivity promotes a phenotype of persistent hyperarousal that reduces the response to minor stressors and amplifies threat perception, maintaining symptoms and social dysfunction. This aspect is prognostically relevant because recovery requires time and multimodal interventions.
In organic forms of CRH excess, particularly ectopic secretion, prognosis depends on tumor control and the speed with which hypercortisolism is reduced. Acute complications of severe hypercortisolism include infections, thrombotic events, metabolic decompensation and marked muscle fragility. In these patients, timely intervention on cortisol is an integral part of prognosis, independently of the subsequent oncological or surgical strategy.
In summary, prognosis is good when dysregulation of the CRH system is recognized early, when functional and organic forms are correctly distinguished, and when treatment is centered on the real pathophysiological drivers. The greatest risk is not only persistence of symptoms, but the progressive transformation of the stress response into a biological risk factor for cardiometabolic and functional complications, which can be prevented with structured follow-up.